When Gallbladder Disease on Mounjaro Becomes a Reason to Stop

Does the Mounjaro label set a gallbladder stopping rule?

No. In adult placebo-controlled Mounjaro trials, acute gallbladder disease (cholelithiasis, biliary colic and cholecystectomy) was reported by 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients. The label's statement for suspected cholelithiasis is gallbladder diagnostic studies and clinical follow-up [1].

The label is explicit about pancreatitis. After starting Mounjaro, it says to observe patients for signs of acute pancreatitis, which may include persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. If pancreatitis is suspected, the label says to discontinue Mounjaro and begin appropriate management. The label does not link that instruction to a cause such as gallstones [1].

Mounjaro is the tirzepatide brand approved for type 2 diabetes and for cardiovascular risk reduction in adults with type 2 diabetes, not for weight loss. The gallbladder rate above comes from the Mounjaro label, not from a weight-management trial [1].

How often does gallbladder disease happen with tirzepatide?

A meta-analysis of nine randomized trials with 9,871 participants found that the composite of gallbladder or biliary disease was significantly associated with tirzepatide compared with placebo or basal insulin (RR 1.97, 95% CI 1.14 to 3.42). The same analysis did not find a significant increase for cholelithiasis, cholecystitis or biliary diseases when each was analyzed alone [2].

A class-wide meta-analysis of 21 trials and 99,599 patients found that GLP-1 receptor agonists increased gallbladder disorders by 26% compared with controls, with tirzepatide among the drugs studied [3].

What about gallbladder surgery?

The label says pulmonary aspiration during general anesthesia or deep sedation has been reported in patients receiving GLP-1 receptor agonists who underwent elective surgeries or procedures, and instructs patients to inform healthcare providers of any planned surgeries or procedures [1]. We found no study that tested continuing Mounjaro during or after cholecystectomy or restarting it afterward.